0000950170-25-026652.txt : 20250225 0000950170-25-026652.hdr.sgml : 20250225 20250225161005 ACCESSION NUMBER: 0000950170-25-026652 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250221 FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cabell Christopher CENTRAL INDEX KEY: 0001814928 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 25663149 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263407249 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 4 1 ownership.xml 4 X0508 4 2025-02-21 0001750149 Inhibikase Therapeutics, Inc. IKT 0001814928 Cabell Christopher 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 false true false false President & Head of R&D false Stock Option (Right to Buy) 2.23 2025-02-21 4 A false 1100705 0 A 2035-02-21 Common Stock 1100705 1100705 D The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date. /s/ Garth Lees-Rolfe, attorney-in-fact 2025-02-25